Market Research Logo

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025

Summary

Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems. MDD is characterized by persistent feelings of sadness, anger, irritability or frustration, loss of interest in activities, and overeating or loss of appetite that can last from days to months, and alternates with episodes of wellness. Little is known about the etiology of MDD; however, research suggests that there may be combinations of genetic, biological, environmental, and psychological factors that potentially increase the risk of MDD.

GlobalData epidemiologists forecast that the 12-month total prevalent cases of MDD in the 7MM will increase from 37,157,683 12-month total prevalent cases in 2015 to 38,142,749 12-month total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.27%. The US will have the highest number of 12-month total prevalent cases of MDD among the 7MM throughout the forecast period, while Japan will have the least number of 12-month total prevalent cases of MDD. As GlobalData epidemiologists used steady prevalence proportions of MDD over the forecast period, the growth in 12-month total prevalent cases in each market can be attributed to the change in population demographics.

GlobalData epidemiologists utilized country-specific and nationally representative peer-reviewed publications to forecast the 12-month total prevalent cases of MDD. The use of consistent methodology across the 7MM allows for a meaningful comparison of the forecast of 12-month total prevalent cases of MDD in these markets. Additionally, the 12-month total prevalent cases of MDD in each of the 7MM are segmented by severity, which can be of importance for predicting the prognosis and course of treatment. Lastly, the 12-month total prevalent cases of MDD in each of the 7MM are further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Scope

  • The Major Depressive Disorder (MDD) EpiCast Report provides an overview of the risk factors and global trends of MDD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of 12-month total prevalent cases of MDD segmented by age (18-19 years, in five-year increments from ages 20-84 years, and ending at ages 85 years and older), sex, and severity in these seven markets.
  • The MDD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The MDD EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global MDD market.
  • Quantify patient populations in the global MDD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MDD therapeutics in each of the markets covered.
  • Identify the percentage of MDD 12-month total prevalent cases by age, sex, and severity.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.4 Forecast Methodology
2.4.1 Sources Used Tables
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for MDD (2015-2025)
2.5.1 12-Month Total Prevalent Cases of MDD
2.5.2 Age-Specific 12-Month Total Prevalent Cases of MDD
2.5.3 Sex-Specific 12-Month Total Prevalent Cases of MDD
2.5.4 Age-Standardized 12-Month Total Prevalence of MDD
2.5.5 12-Month Total Prevalent Cases of MDD by Severity
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 Physicians and Specialists Included in this Study
3.3 About the Authors
3.3.1 Epidemiologists
3.3.2 Reviewers
3.3.3 Global Director of Therapy Analysis and Epidemiology
3.4 About GlobalData
3.5 About EpiCast
3.6 Disclaimer
1.1 List of Tables
Table 1: DSM-IV Diagnostic Criteria for MDD
Table 2: Risk Factors and Comorbidities for MDD
Table 3: Prevalence of the Most Frequent Psychiatric Comorbidities in Individuals With and Without MDD, Ages 18-64 Years
Table 4: 7MM, Total Prevalence (%) of MDD According to the DSM-IV Criteria, ≥18 Years
Table 5: 7MM, Total Prevalence (%) of MDD According to the DSM-III Criteria
Table 6: 7MM, Sources Used to Forecast the 12-Month Total Prevalence of MDD
Table 7: Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD by Severity
Table 8: 7MM, Sources Not Used in Epidemiological Forecast for the 12-Month Total Prevalent Cases of MDD
Table 9: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18Years, Both Sexes, N, Selected Years 2015-2025
Table 10: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N (Row %), 2015
Table 11: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N (Row %), 2015
Table 12: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016
1.2 List of Figures
Figure 1: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18 Years, Both Sexes, N, 2015-2025
Figure 2: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N, 2015
Figure 3: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N, 2015
Figure 4: 7MM, Age-Standardized 12-Month Total Prevalence (%) of MDD, by Sex, Ages ≥18 Years, 2015
Figure 5: 7MM, 12-Month Total Prevalent Cases of MDD by Severity, Both Sexes, Ages ≥18 Years, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report